By down-regulating the phosphorylation of PI3K and AKT, BYD may inhibit the expression of inflammatory factors and inflammatory cells induced by the activation of downstream pathways, thus alleviating airway inflammation in allergic asthma mice, implying the potential effect of BYD in the treatment of asthma. The gene discussed is AKT1; the disease is allergic asthma.